Jun 23, 2025, 23:10
We are Excited to Share That JIPO 2024 Impact Factor is 3.2 – Journal of Immunotherapy and Precision Oncology
Journal of Immunotherapy and Precision Oncology shared a post on LinkedIn:
“We are excited to share that JIPO 2024 Impact Factor is 3.2.
This is the first impact factor reported for the Journal.
This major milestone and achievement would not have happened without the dedication and high professional performance of the Editorial team led by Dr. Aung Naing and to the high quality contributions of the authors and reviewers.
We thank all those who contributed to this achievement and looking forward to continuing support of all involved.”
More posts featuring Journal of Immunotherapy and Precision Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 16, 2025, 17:55
Jul 16, 2025, 17:38
Jul 16, 2025, 17:37
Jul 16, 2025, 17:04
Jul 16, 2025, 16:51
Jul 16, 2025, 16:34
Jul 16, 2025, 16:18